Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.14M Buy
4,375
+84
+2% +$21.5K 0.35% 63
2026
Q2
$1.07M Buy
4,291
+79
+2% +$17K 0.32% 69
2026
Q1
$916K Buy
4,212
+27
+0.6% +$5.99K 0.32% 74
2025
Q4
$956K Buy
4,185
+802
+24% +$183K 0.31% 70
2025
Q3
$783K Sell
3,383
-91
-3% -$18.5K 0.31% 68
2025
Q2
$645K Sell
3,474
-509
-13% -$94.6K 0.3% 79
2025
Q1
$835K Sell
3,983
-128
-3% -$24.9K 0.41% 63
2024
Q4
$731K Buy
+4,111
New +$756K 0.37% 64

Other funds holding ABBV

Argentarii's ABBV Position: Q3 2026 in Review

Argentarii increased its AbbVie (ABBV) stake by 2% in Q3 2026, buying an estimated $21.5K and bringing the position to 4,375 shares worth $1.14M. The position accounts for 0.35% of the portfolio, ranked #63.

Argentarii first reported a position in ABBV in Q4 2024 and has held it in 8 quarters since. 1,995 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Argentarii held 4,375 shares of AbbVie worth $1.14M as of Q3 2026.
  • Argentarii bought 84 AbbVie shares in Q3 2026, an estimated $21.5K.
  • AbbVie made up 0.35% of Argentarii's portfolio in Q3 2026, its #63 holding.
  • Argentarii first reported a position in AbbVie in Q4 2024 and has held it in 8 quarters since.
  • 1,995 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Argentarii's 13F filing for Q3 2026, filed 28 Oct 2026.